Last reviewed · How we verify
Tinzaparin, High dose prophylactic anticoagulation — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Tinzaparin, High dose prophylactic anticoagulation (Tinzaparin, High dose prophylactic anticoagulation) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tinzaparin, High dose prophylactic anticoagulation TARGET | Tinzaparin, High dose prophylactic anticoagulation | Assistance Publique - Hôpitaux de Paris | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tinzaparin, High dose prophylactic anticoagulation CI watch — RSS
- Tinzaparin, High dose prophylactic anticoagulation CI watch — Atom
- Tinzaparin, High dose prophylactic anticoagulation CI watch — JSON
- Tinzaparin, High dose prophylactic anticoagulation alone — RSS
Cite this brief
Drug Landscape (2026). Tinzaparin, High dose prophylactic anticoagulation — Competitive Intelligence Brief. https://druglandscape.com/ci/tinzaparin-high-dose-prophylactic-anticoagulation. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing